FDA
-
-
-
-
-
-
-
Crinetics Presents Full Results From Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH) in Oral Presentation at ENDO 2026
-
-
-
-
-
-
-
Crinetics Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update
-
-
-
-
-
-
-
Crinetics Pharmaceuticals to Participate in Two Upcoming Investor Conferences in March
-
-
-
-
-
-
-
Crinetics announces $350 million public offering of common stock
-
-
-
-
-
-
-
Crinetics Pharmaceuticals to Participate in The 44th Annual J.P. Morgan Healthcare Conference
-
-
-
-
-
-
-
Crinetics Pharmaceuticals Announces November 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
-
-
-
-
-
-
Crinetics (CRNX) PT Raised to $85 at Jones Trading
-
326,111 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

